Hyundai Bio Submits Clinical Phase 2 Trial Plan Application for COVID-19 Treatment
[Asia Economy Reporter Minji Lee] Hyundai Bio announced on the 21st that it has submitted the phase 2 clinical trial application for the COVID-19 treatment CP-COV03 to the Ministry of Food and Drug Safety.
Hot Picks Today
Taking Annual Leave and Adding "Strike" to Profiles, "It Feels Like Samsung Has Collapsed"... Unsettled Internal Atmosphere
- There Is a Distinct Age When Physical Abilities Decline Rapidly... From What Age Do Strength and Endurance Drop?
- "One Comment Could Lead to a Report": 86% of Elementary Teachers Feel Anxious; Half Consider Resignation or Career Change
- "After Vowing to Become No. 1 Globally, Sudden Policy Brake Puts Companies’ Massive Investments at Risk"
- On Teacher's Day, a Student's Gifted Cake Had to Be Cut into 32 Pieces... Why?
The company stated, "Niclosamide is expected to have high antiviral efficacy against coronaviruses, but it has low bioavailability," and added, "CP-COV03 improves the bioavailability of niclosamide, raising expectations for its potential as a COVID-19 treatment."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
